Lead Plaintiff Deadline: December 07, 2020
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(1) comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of the Company’s lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
In order to be included in the lawsuit, you must have incurred a loss on shares of Mesoblast purchased or acquired during the class period listed above.
If you suffered a loss in Mesoblast during the relevant time frame, you have until December 07, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.